About

Vast experience: check. Deep expertise: check. Easy accessibility: check. After decades of investing from offices in the most important centers of biotechnology worldwide, Abingworth offers entrepreneurs an unmatched combination of all three of these key attributes.

Watch The Abingworth Edge

ABINGWORTH'S TRANSATLANTIC REACH

With offices in the world's key biotech centres, we support entrepreneurs in both the US and Europe.

We benefit from our transatlantic approach through a broader understanding of competitive geographies, expertise in many different capital markets, access to a larger pool of management talent and wider scientific networks.

162Life Science Companies

38Product Approvals

27Abingworth Team

12Life Science Funds Raised

2017Abingworth Bioventures 7

2016Abingworth Clinical Co-Development

2012Abingworth Bioventures VI

2008Abingworth Bioventures V Growth Equity

2007Abingworth Bioventures V

2005Abingworth BioEquities

2003Abingworth Bioventures IV

2002Abingworth Bioventures IIa

2001Abingworth Bioventures III

1997Abingworth Bioventures II

1992Abingworth Bioventures

1987Biotechnology Venture Fund

ABVII, III and IV are in liquidation.
BVF, ABV and ABVIIa are already liquidated.

12 LIFE SCIENCE FUNDS

Abingworth has raised 12 funds dedicated to investing in life sciences and healthcare. Our most recent, Abingworth Bioventures 7 and Abingworth Clinical Co-Development Fund, raised $315 million and $108 million respectively and are actively investing.

Venture Funds

Our venture funds invest across our broad strategic areas of venture capital, clinical co-development, VIPEs and public markets. They focus primarily on private companies but invest a percentage of their value in public companies.

List all funds

Latest Updates

One of the joys of working with small companies is seeing the speed with which they make progress, and we are always proud to share their news – the latest of which is shown below.

6th August 2020

Dicerna Announces Positive Clinical Data for Investigational Treatments RG6346 for Chronic Hepatitis B Virus and Nedosiran for Primary Hyperoxaluria, and Presents Preclinical Data Applying RNAi Technology in New Tissues

27th July 2020

Venatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Priority Pathogen

22nd July 2020

Nouscom highlights cutting-edge science that led to the design of NOUS-209, a potential off-the-shelf neoantigen cancer vaccine for tumors with Microsatellite Instability